Therapeutic peptides

Future Medicinal Chemistry

Volumn 4, Issue 12, 2012, Pages 1527-1531

  Albericio, Fernando ^a   Kruger, Hendrik G ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; BRENTUXIMAB VEDOTIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DELCASERTIB; ECALLANTIDE; ICATIBANT; LIRAGLUTIDE; PEPTIDE DERIVATIVE; ROMIDEPSIN; TELAPREVIR; TELAVANCIN;

ANGIONEUROTIC EDEMA; BIOFILM; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; HEPATITIS C; HODGKIN DISEASE; HUMAN; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SKIN INFECTION;

ANGIOEDEMAS, HEREDITARY; BACTERIAL INFECTIONS; DRUG APPROVAL; DRUG DESIGN; HUMANS; LYMPHOMA; PEPTIDES; PRODRUGS; RNA VIRUS INFECTIONS;

EID: 84865491407     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.94     Document Type: Review

References (24)

1. Joint Research Centre European Commission. The 2011 EU Industrial R&D Investment Scoreboard. Publications Office of the EU, London, UK (2011).
2. Hughes B. 2009 FDA drug approvals. Nat. Rev. Drug Discov. 9(2), 89-91 (2010).
3. Mullard A. 2010 FDA drug approvals. Nat. Rev. Drug Discov. 10(2), 82-85 (2011).
4. Mullard A. 2011 FDA drug approvals. Nat. Rev. Drug Discov. 11(3), 91-94 (2012).
5. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010 J. Nat. Prod. 75(3), 311-335 (2012).
6. Ganesan A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol. 12, 306-317 (2008).
7. Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking: current status and future challenges. Proteins 65, 15-26 (2006). (Pubitemid 44320611)
8. Marrone JT, Briggs MJ, Mccammon A. Structure-based drug design: computational advances. Annu. Rev. Pharmacol. Toxicol. 37, 71-90 (1997).
9. Sukumarand N, Das S. Current trends in virtual high throughput screening using ligand-based and structure-based methods. Comb. Chem. High Throughput Screen. 14, 872-888, (2011).
10. Caflisch A, Walchli R, Ehrhardt C. Computer-aided design of thrombin inhibitors. News Physiol. Sci. 13, 182-189 (1998). (Pubitemid 128676274)
11. Danho W, Swistok J, Khan W et al. Opportunities and challenges of developing peptide drug in the pharmaceutical industry. In: Peptides for Youth. The Proceedings of the 20th American Peptide Symposium. Del Valle S, Escher E, Lubell WD (Eds). Springer Science and Business Media, New York, NY, USA, 467-468 (2009).
12. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov. Today 15(1/2), 40-56 (2010).
13. Ayoub M, Scheidegger D. Peptide drugs, overcoming the challenges, a growing business. Chem. Today 24, 46-48 (2006). (Pubitemid 44475342)
14. Bruckdorfer T, Marder O, Albericio F. From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Curr. Pharm. Biotech. 5, 29-43 (2004). (Pubitemid 38404704)
15. Zompra AZ, Galanis AS, Werbitzky O, Albericio F. Manufacturing peptides as active pharmaceutical ingredients. Future Med. Chem. 1(2), 361-377 (2009).
16. Pease JE, Horuk R. Small molecule antagonists of chemokine receptors - is promiscuity a virtue? Curr. Topics Med. Chem. 10(13), 1351-1358 (2010).
17. Meanwell NA. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 24(9), 1420-1456 (2009).
18. Walensky LD. Interview with Loren D Walensky. Future Med. Chem. 4(12), 1537-1539 (2012).
19. Almansour NM, Pirogova E, Coloe PJ, Cosic I, Istivan TS. Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study. Future Med. Chem. 4(12), 1553-1565 (2012).
20. Dawgul M, Baranska-Rybak W, Kamysz E, Karafova A, Nowicki R, Kamysz W. Activity of short lipopeptides and conventional antimicrobials against planktonic cells and biofilms formed by clinical strains of Staphylococcus aureus. Future Med. Chem. 4(12), 1541-1551 (2012).
21. Jacobsen AS, Jenssen H. Human cathelicidin LL-37 prevents bacterial biofilm formation. Future Med. Chem. 4(12), 1587-1599 (2012).
22. Ahrens VM, Bellmann-Sickert K, Beck-Sickinger AG. Peptides and peptide conjugates: therapeutics on the upward path. Future Med. Chem. 4(12), 1567-1586 (2012).
23. Roxin Á, Zheng G. Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides. Future Med. Chem. 4(12), 1601-1618 (2012).
24. Audie J, Swanson J. Recent work in the development and application of protein-peptide docking. Future Med. Chem. 4(12), 1619-1644 (2012).